Overview

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Ful

Status:
Completed

Trial end date:
2016-11-28

Target enrollment:

Participant gender:

Summary

The study allowed continued safety follow-up of patients who were on single agent dovitinib or dovitinib in combination with fulvestrant treatment in a Novartis-sponsored study which had met its primary endpoint and were benefiting from the treatment as judged by the investigator.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Estradiol
Fulvestrant